AstraZeneca on Tuesday agreed to buy vaccine developer Icosavax in a deal valued at up to $1.1 billion to bolster its respiratory syncytial virus (RSV) vaccine portfolio.
The deal values Icosavax at $15 per share in cash at closing, plus a non-tradable contingent value right for up to $5 per share in cash if certain milestones are met.
The upfront payment of $15 apiece represents a premium of about 43% to U.S.-listed Icosavax's last close.
https://finance.yahoo.com/news/1-astrazeneca-buy-rsv-vaccine-071944311.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.